<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04134845</url>
  </required_header>
  <id_info>
    <org_study_id>190797</org_study_id>
    <nct_id>NCT04134845</nct_id>
  </id_info>
  <brief_title>Feasibility of Dantrolene to Study RyR2 Inhibition to Prevent Ventricular Arrhythmias</brief_title>
  <official_title>A Pilot Trial to Demonstrate the Feasibility of Using Dantrolene to Study RYR2 Inhibition to Prevent Ventricular Arrhythmias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label trial (N=5 participants) to demonstrate the feasibility of using I.V.
      dantrolene to study the effect of RyR2 inhibition on cardiac electrophysiology, hemodynamics
      and ventricular arrhythmia inducibility in patients with structural heart disease referred
      for VT ablation. The investigators will also explore the pharmacokinetic/pharmacodynamic
      relationship of I.V. dantrolene and it short-term effect on specific cardiac
      electrophysiologic and hemodynamic parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dantrolene inhibits RyR2-mediated Ca leak but does not block the Na channel. By reducing
      spontaneous Ca leak, dantrolene may reduce Ca mediated Na channel inactivation thereby
      reversing slowed conduction in abnormal tissues. It also may reduce SK channel activation
      thereby reversing shortened refractoriness in abnormal tissues. The investigators will test
      the idea that selective RyR2 inhibition with dantrolene will reduce VT/VF in structural heart
      disease by reversing proarrhythmic changes in conduction and refractoriness that promote
      scar-related reentry.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 7, 2019</start_date>
  <completion_date type="Actual">February 10, 2020</completion_date>
  <primary_completion_date type="Actual">February 10, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inducibility of sustained VT/VF by standardized ventricular stimulation protocol</measure>
    <time_frame>10 minutes post drug infusion</time_frame>
    <description>Post drug ventricular stimulation with RV ventricular catheter in the RV apex with increasing extra stimuli with planned decrement stimuli by 10 ms to ERP. Outcome is measured as Ventricular inducibility yes/no.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inducibility of sustained VT/VF by standardized ventricular stimulation protocol</measure>
    <time_frame>10 minutes</time_frame>
    <description>measured as ordinal variable for stage of ventricular stimulation protocol;specific step by step V-stim research protocol will be followed with single extra stimuli up to six extra stimuli added to VERP. What stage of Inducible VT will be recorded.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serial heart rate measurements</measure>
    <time_frame>pre drug x 1, 5 minute, 10 minute and 20 minutes</time_frame>
    <description>Heart rate- BPM</description>
  </other_outcome>
  <other_outcome>
    <measure>Serial Blood pressure measurements</measure>
    <time_frame>pre drug x 1, 5 minute, 10 minute and 20 minutes</time_frame>
    <description>BP - mmHg</description>
  </other_outcome>
  <other_outcome>
    <measure>Serial arterial O2 sats</measure>
    <time_frame>pre drug x 1, 5 minute, 10 minute and 20 minutes</time_frame>
    <description>O2 sats %, percent of Hgb</description>
  </other_outcome>
  <other_outcome>
    <measure>Serial mixed venous O2 sats- measured from PA catheter</measure>
    <time_frame>pre drug x 1, 5 minute, 10 minute and 20 minutes</time_frame>
    <description>mixed venous O2 sats % percent of Hgb</description>
  </other_outcome>
  <other_outcome>
    <measure>Serial PA measurements</measure>
    <time_frame>pre drug x 1, 5 minute, 10 minute and 20 minutes</time_frame>
    <description>PA- mmHg</description>
  </other_outcome>
  <other_outcome>
    <measure>Serial Pulmonary Cap. Wedge pressure measurements</measure>
    <time_frame>pre drug x 1, 5 minute, 10 minute and 20 minutes</time_frame>
    <description>PCWP- mmHg</description>
  </other_outcome>
  <other_outcome>
    <measure>Per the pharmacokinetics measurements that will be collected and measured offline-drug half life</measure>
    <time_frame>5, 10, 15, 20 minutes, 1-4 hours, 6-12 hours,16-24 hours and optional 28-36 hours</time_frame>
    <description>half-life (h)</description>
  </other_outcome>
  <other_outcome>
    <measure>Maximum observed plasma concentration</measure>
    <time_frame>5, 10, 15, 20 minutes, 1-4 hours, 6-12 hours,16-24 hours and optional 28-36 hours</time_frame>
    <description>Cmax (ng/ml)</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to reach maximum observed plasma concentration</measure>
    <time_frame>5, 10, 15, 20 minutes, 1-4 hours, 6-12 hours,16-24 hours and optional 28-36 hours</time_frame>
    <description>Tmax (h)</description>
  </other_outcome>
  <other_outcome>
    <measure>Area under the concentration-time curve from zero to infinity</measure>
    <time_frame>5, 10, 15, 20 minutes, 1-4 hours, 6-12 hours,16-24 hours and optional 28-36 hours</time_frame>
    <description>AUC- h ng/ml</description>
  </other_outcome>
  <other_outcome>
    <measure>Ventricular effective refractory period pre/post Dantrolene</measure>
    <time_frame>Pre-drug, 5, 10,15 and 20 minute post-drug</time_frame>
    <description>VERP measured at 500 ms</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>Dantrolene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravenous administration of dantrolene; 1 mg/ kg IV over 1 minute, one time dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dantrolene</intervention_name>
    <description>muscle relaxant</description>
    <arm_group_label>Dantrolene</arm_group_label>
    <other_name>Dantrium, Ryanodex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Greater than or equal to 18 years of age

          -  Able to give written informed consent

          -  Referred for catheter-based VT ablation

          -  Structural heart disease (cardiomyopathy or RV/LV scar)

        Exclusion Criteria:

          -  Mechanical ventricular support (e.g. LVAD, ECMO)

          -  NYHA class IV heart failure

          -  LVEF &lt; 20%

          -  Morbid obesity (BMI &gt; 40 kg/m2)

          -  Chronic liver disease (Child Pugh class A-C)

          -  Current use of calcium channel blockers

          -  Neuromuscular disorder (e.g. muscular dystrophy)

          -  Chronic obstructive pulmonary disease or restrictive lung disease requiring oxygen

          -  Therapy or history of intubation

          -  Pregnant or nursing

          -  History of dysphagia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Stevenson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 10, 2019</study_first_submitted>
  <study_first_submitted_qc>October 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2019</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>William Stevenson</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Ventricul Tachycardia ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dantrolene</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

